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Abstract 
Background. Pathological grading of tumors is a way to measure biological aggressiveness. 
In lung neuroendocrine tumors (NET), grading is tautologically included into the current 2015 WHO 
histologic classification. Little is known, however, about alternative grading systems in lung NET. 
Methods. Through an extensive search of the English literature on lung NET (updated to April 
2016), the following key questions were addressed: a) current concepts of grading; b) clinicians’ 
requests for grading; c) functional parameters for grading; d) Ki-67 labeling index (LI) for grading; e) 
towards an effective pathology grading system. 
Results. There is some room for inconsistency in the histologic classification of lung NET, 
likely due to the varying attribution of defining criteria. Innovative diffusion-weighted imaging upon 
magnetic resonance or molecular analysis could help separate indolent from aggressive lung NET, thus 
integrating a grading approach other than histology. Troubles in the clinical handling of metastatic or 
individual tumors when relying on morphology alone support the development of a lung-specific grading 
system for the more accurate prediction of prognosis and planning therapy in individual patients. To 
integrate the 2015 WHO classification using innovative grading based on Ki-67 LI, mitotic count and 
necrosis, a new proposal is emerging where three categories of lung NET are identified, namely Lu-NET 
G1, Lu-NET G2 and Lu-NET G3, which would allow tumors with similar behavior and therapy to be 
better handled according to their own biological potential. 
Conclusion. This new formulation of lung NET grading could have clinical relevance for the 
individual handling of patients.  
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Introduction 
 Pathologic tumor grading is an operational way to express the aggressiveness potential of 
human malignancies resulting in dismal prognosis and reduced survival (Edge et al., 2010; Sobin et al., 
2010) or to quantify the risk of precursor lesions (dysplasia and in situ carcinoma) to give rise to or 
associate with invasive tumors (Holland et al., 1994; Leong et al., 2001; Breuer et al., 2005; Ishizumi et 
al., 2010; Yatabe et al., 2011; Basturk et al., 2015b; Bennett et al., 2015; Geetha et al., 2015; Kuijpers et 
al., 2015; Travis et al., 2015a). Tools for grading are usually specific morphologic attributes, either 
quantitative or qualitative, which are deemed to accurately parallel the natural history of tumors, thereby 
predicting the ultimate behavior at the level of an individual patient’s cancer (Holland et al., 1994; Breuer 
et al., 2005; Edge et al., 2010; Ishizumi et al., 2010; Sobin et al., 2010). 
Traditionally, tumor grading has adopted histologic and/or cytological traits (cell differentiation) 
to create two-tier to four-tier scales based on a steady increase in cell abnormalities, based on the 
premise that reduced resemblance of tumors with respect to the normal cell counterpart is associated 
with a higher propensity to grow and disseminate, with relentlessly reduced survival (see 
http://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet and (Edge et 
al., 2010; Sobin et al., 2010). Currently, the relevance of tumor grading to planning patient treatment or 
staging is greater for certain types of cancer, such as tumors affecting soft tissue (Coindre et al., 2001; 
Sobin et al., 2010), bone (CDM et al., 2013), brain (Louis et al., 2016), breast (Lakhani et al., 2012), 
prostate (Kryvenko and Epstein, 2016) and kidney (H et al., 2016), in which there is a case mix of 
indolent to highly aggressive tumors. At variance are highly deadly cancers, such as lung (Barletta et al., 
2010; Kadota et al., 2012b; Kadota et al., 2012a; Sigel et al., 2012; Warth et al., 2012; Westaway et al., 
2013; Zhao et al., 2015; Travis et al., 2016a; Warth et al., 2016; Weichert et al., 2016), pancreas 
(Luttges et al., 2000; Basturk et al., 2015b; Sigel et al., 2015) or ovary (Ryu et al., 2009; Sica et al., 
2010; Bodurka et al., 2012), which have much less effective grading models, and the relevant clinical 
context of application is still unclear. 
Traditionally, grading systems have been featured on G1 to G3 scales by inversely linking cell 
differentiation to clinical behavior according to defining schemes, which depend on diverse institutions or 
tumor types (Sundquist et al., 1999; Coindre et al., 2001; Sobin et al., 2010; Kryvenko and Epstein, 
2016). Briefly, G1 tumors indicate slow-growing lesions closely looking like the normal cell counterpart 
they have originated from or are differentiating towards. G3 tumors refer to fast-growing lesions 
composed of anaplastic cells with no definite signs of differentiation. G2 tumors comprise intermediate 
lesions in terms of morphology traits and clinical aggressiveness (Edge et al., 2010; Sobin et al., 2010). 
It is evident, however, that such cell differentiation-dependent grading systems may be disappointing 
due to the objective difficulty in ascertaining cell lineages for ultimate comparison (for instance, in 
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tumors with uncertain cell derivation) or attributing reproducible morphologic traits to each defining 
category, thus resulting in some intra- and inter-observer inconsistency (Kaye et al., 2016; Kuijpers et al., 
2016; Kweldam et al., 2016; Priemer et al., 2016). 
To overcome these drawbacks, many grading systems have adopted multiple criteria selected 
by multivariate analysis of several histological features, which are diversely scored independently of 
each parameter to obtain a final grade by adding all attributed scores (Thomas et al., 2009; Kryvenko 
and Epstein, 2016; Louis et al., 2016; Moch et al., 2016). In lung adenocarcinoma, for example, grading 
has been greatly strengthened by crossing tumor architecture (Sica et al., 2010) and different 
expression levels of mitotic count, at least for resection specimens representing stage I of disease 
(Kadota et al., 2012a). 
As grade would mirror the capability of tumor cells to grow and spread (Edge et al., 2010; 
Sobin et al., 2010), it would be an intensive property of tumors independent of their extension (and 
hence stage), exactly as the temperature of a body is proportional to the amplitude of molecular 
vibrations but not to the quantity of thermal energy (Gibbs free enthalpy) (Rietman et al., 2016), which in 
turn depends on mass. In this scenario, high-grade tumors are expected to behave aggressively even if 
of small size or serendipitously confined to the origin organ, exactly as small-sized bodies have limited 
heat capacity but may have high temperature. Tumor grade is not necessarily a stable and 
unchangeable property of tumors but may worsen over time according to a linear progression scheme of 
molecular and morphologic changes or a sudden emergence of aggressive cell subsets (Breuer et al., 
2005; Ishizumi et al., 2010; Yatabe et al., 2011), either spontaneously (de novo carcinogenesis) or 
triggered by therapy intervention for selective pressure on resistant clones (Breuer et al., 2005; Ishizumi 
et al., 2010; Sequist et al., 2011; Yatabe et al., 2011). 
Most grading systems have been variably based on cancer development-related defining 
criteria, such as necrosis, cell proliferation (mitotic count, cell cycle-related antigens), cell differentiation 
(size, nuclear-cytoplasmic ratio, nuclear features, growth patterns), neo-angiogenesis or changes at the 
tumor-stroma interface (budding) (Luttges et al., 2000; Coindre et al., 2001; Ryu et al., 2009; Barletta et 
al., 2010; Sica et al., 2010; Sobin et al., 2010; Bodurka et al., 2012; Kadota et al., 2012b; Kadota et al., 
2012a; Lakhani et al., 2012; Rindi et al., 2012; Sigel et al., 2012; Warth et al., 2012; Westaway et al., 
2013; Pelosi et al., 2014b; Basturk et al., 2015b; Sigel et al., 2015; Zhao et al., 2015; H et al., 2016; 
Kryvenko and Epstein, 2016; Louis et al., 2016; Travis et al., 2016a; Warth et al., 2016; Weichert et al., 
2016). It is clear that greater clinical aggressiveness of tumors results in a reduced likelihood of 
effectively stratifying patients in sub-categories by attaining grading criteria. As lung neuroendocrine 
tumors (NET) are behaviorally heterogeneous, ranging from quite indolent to very aggressive tumors 
(Rekhtman, 2010; Pelosi et al., 2014a; Pelosi et al., 2014b; Pelosi et al., 2014c; Travis et al., 2015), a 
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grading system is potentially useful to stratify these tumor patients at the level of individual patients' 
cancers (Rindi et al., 2014b). 
This article is intended to address the issue of grading in lung NET by reviewing relevant 
information on pathology, innovative imaging, molecular profiling and the Ki-67 labeling index (Ki-67 LI) 
in light of current challenging requests by clinicians. As lung NET needs to be clinically stratified to plan 
treatments, the question is not whether to grade or not to grade these tumors but rather how best to 
grade them. The hope is that integrating traditional morphology with closer criteria to cancer biology will 
allow researchers to place an innovative terminology into context for the best handling of lung NET at 
the level of individual patients' cancers. 
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Materials and methods 
A detailed bibliography search (not a systematic review) on grading in lung NET was 
performed until June 2016. The bibliography search was limited to English literature, with only full 
papers of peer-reviewed journals being on record. A practical key-question list of pathology, clinics, 
imaging and molecular issues relative to grading in lung NET was prepared, with several items included 
in the search: carcinoid, typical, atypical, small cell, large cell, LCNEC, SCLC, grading, mitoses, count, 
necrosis, Ki-67, prognosis, survival, molecular, aggressiveness, therapy, cancer development, 
biomarker, gene, sequencing, mutation, positron emission tomography, fluoro-deoxy-glucose, 
octreoscan, somatostatin receptor, imaging, magnetic resonance, and weighted diffusion. 
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Results 
The paper aims to address the current state of the art for grading in lung NET, providing 
possible interpretation keys and mediating a final managerial proposal. In detail, a few key questions 
were herein addressed: a) current concepts of grading; b) clinicians’ requests for grading; c) functional 
parameters for grading; d) Ki-67 labeling index for grading; e) towards an effective pathology grading 
system. The following presentation will address these key questions in light of recently published papers, 
with relevant key points summing up major interpretation issues included at the end of each item. 
 
 
a) Current concepts of grading 
Lung NET are currently catalogued according to diagnostic criteria based on morphology, 
which have been confirmed to have substantial validity in the last three WHO classifications (Travis et 
al., 1999; Travis et al., 2004; Travis et al., 2015b). They thus comprise four histological variants, namely 
typical carcinoid (TC), atypical carcinoid (AC), large-cell neuroendocrine carcinoma (LCNEC) and small-
cell carcinoma (SCC), which have recently been pushed to enter a unique box of tumors showing NE 
morphology and differentiation along with pre-invasive lesions, such as diff se idiopathic pulmonary 
neuroendocrine cell hyperplasia (DIPNECH) with a chance for the development of carcinoids (Travis et 
al., 2015b). In particular, LCNEC has been removed from the confusing and all-inclusive chapter of 
large-cell carcinoma in the 1999 and 2004 WHO classifications (Travis et al., 1999; Travis et al., 2004). 
SCC is no longer considered a separate tumor entity that is simply opposed to non-small-cell lung 
carcinoma (NSCLC) for clinical purposes (Travis et al., 2004), and the debated term of NSCLC with NE 
differentiation (NSCLC-ND) has been eliminated because of uncertain clinical value (Pelosi et al., 
2003b; Howe et al., 2005; Ionescu et al., 2007; Segawa et al., 2009; Sterlacci et al., 2009; Petrovic et al., 
2011; Gottschling et al., 2013; Derks et al., 2016a) (the current recommendation is not to perform 
Immunohistochemistry (IHC) for NE markers if the relevant morphology is lacking, whatever material is 
dealt with) (Travis et al., 2013; Travis et al., 2015a; Travis et al., 2016b). 
A large body of literature has been supporting the notion that the stratification of lung NET 
according to epidemiology (age, sex, smoking habits), molecular knowledge (association with MEN1 
syndrome, menin, RB1, TP53 mutations and other gene pathway alterations), clinics (occurrence of 
regional lymph node and distant metastases, association and type of para-neoplastic syndromes, 
response to different therapies) and behavior (survival) fits well with an operational three-tier prognostic 
arrangement paralleling a steady increase in tumor aggressiveness (Godwin and Brown, 1977; 
Asamura et al., 2006; Moran and Suster, 2007; Righi et al., 2007; Moran et al., 2009; Rekhtman, 2010; 
Righi et al., 2010a; Righi et al., 2010b; Travis, 2010; Pelosi et al., 2014a; Pelosi et al., 2014b; Pelosi et 
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al., 2014c; Righi et al., 2014; Rindi et al., 2014b; Rossi et al., 2014; Travis, 2014; Caplin et al., 2015; 
Filosso et al., 2015b; Pelosi et al., 2015c; Travis et al., 2015a). In this continuous spectrum, however, 
only TC and AC are behaviorally distinguishable from each other (Garcia-Yuste et al., 2000; Garcia-
Yuste et al., 2007; Canizares et al., 2014; Garcia-Yuste and Matilla, 2014), while LCNEC and SCC often 
merge with overlap of survival curves when limiting to morphology (Garcia-Yuste et al., 2000; Jones et 
al., 2004; Travis, 2010; Rossi et al., 2014; Travis, 2014; Naidoo et al., 2016).  
In the past, there had been attempts to introduce a concept of grading in the classification of 
NET (Capella et al., 1994, 1995; Wick, 2000; Cerilli et al., 2001; Moran and Suster, 2007; Moran et al., 
2009; Pelosi et al., 2014a; Rindi et al., 2014b; Pelosi et al., 2015c), by variably intermingling the notion 
of cell differentiation (Capella et al., 1994, 1995; Wick, 2000; Cerilli et al., 2001; Axiotis, 2002; Huang et 
al., 2002), applying different thresholds to current defining criteria (Axiotis, 2002; Huang et al., 2002) or 
extending to them the taxonomy devised for gastroenteropancreatic (GEP) NE neoplasms (NEN) 
(Capella et al., 1994, 1995; Zahel et al., 2012). These proposals, however, failed to become widespread, 
likely due to historical reasons and a purported lack of undisputable clinical benefits compared to 
existing WHO classifications (Travis et al., 1999; Travis et al., 2004; Travis et al., 2015a). In particular 
and at variance with GEP NEN (Klimstra et al., 2010b; Klimstra et al., 2010a; Yang et al., 2013; Klimstra 
et al., 2015; Klimstra, 2016), cell differentiation is not an accepted criterion for classifying lung (and even 
thymus) NET (Marx et al., 2015; Travis et al., 2015b), although TC and AC are as a whole de facto well-
differentiated tumors in both anatomical sites as opposed to poorly differentiated LCNEC and SCC 
(Caplin et al., 2015) when using morphology and the relative amount of dense-core NE granules 
(highlighted by chromogranin A IHC) as judgment criteria (Klimstra et al., 2010a; Caplin et al., 2015; 
Travis et al., 2015b). However, SCC remains a mere histologic diagnosis in both the lung and the 
thymus, which lacks obvious NE morphology apart from nuclear characteristics (size and chromatin 
texture) and does not require NE marker demonstration for ultimate diagnosis (although it is detectable 
in 90% or more of cases and strongly recommended by current guidelines) (Caplin et al., 2015; 
Marchevsky and Wick, 2015; Marx et al., 2015; Travis et al., 2015a). In turn, LCNEC requires NE 
morphology and clear-cut NE differentiation in 10% or more of the tumor cells at either site to distinguish 
them from conventional carcinomas (Rossi et al., 2014; Caplin et al., 2015; Marx et al., 2015; Travis et 
al., 2015a). Therefore, it is not surprising that some discrepancy may arise in AC (tautologically well 
differentiated) with respect to the irregular distribution of dense-core NE granules or borderline (around 
ten) mitosis counts (Caplin et al., 2015) or in SCC (tautologically poorly differentiated) because of the 
unexpected abundance of dense core granules (see Figure 1 depicting an example of differentiation-
discrepant lung SCC). 
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At variance with GEP NET (Rindi et al., 2006; Rindi et al., 2012; Rindi et al., 2014a), 
morphologic classification in the lung (and thymus)  has been tautologically equated to grading (Marx et 
al., 2015; Travis et al., 2015b). Accordingly, TC and AC comprise low-grade and intermediate-grade 
malignant NE tumors with long-term and intermediate survival rates, respectively, LCNEC and SCC 
encompass full-blown high-grade NE carcinomas, both with dismal prognoses (Pelosi et al., 2014a; 
Pelosi et al., 2014b; Marx et al., 2015; Pelosi et al., 2015c; Travis et al., 2015b). 
The diagnosis of NET is a stepwise process (Franks and Galvin, 2008) where NE morphology, 
number of mitoses per 2 mm2, occurrence and qualitative extent of tumor necrosis and cytological 
details are used to catalogue TC, AC, LCNEC and SCC (Table 1). The Ki-67 antigen labeling index (Ki-
67 LI) is significantly ranked among these four categories of tumors (recently reviewed by Pelosi et al.) 
(Pelosi et al., 2014c), but it is currently not advisable to perform this technique using proliferation 
markers other than mitotic count to diagnose because of the partial overlap of Ki-67 LI values between 
biologically adjacent tumor variants (TC vs. AC; AC vs. LCNEC; LCNEC vs. SCC) (Pelosi et al., 2014c; 
Travis et al., 2015b). While IHC for NE markers is recommended‚—even if not mandatory—for an 
ultimate diagnosis of lung NET (Caplin et al., 2015; Travis et al., 2015b), the exclusion of Ki-67 LI from 
classification is less understandable even if it has been ascribed to imperfect inter-observer 
reproducibility and sub-optimal correlation with defining criteria, namely mitotic count and necrosis 
(Pelosi et al., 2014a; Pelosi et al., 2014b; Pelosi et al., 2014c). However, the same difficulty (and hence 
overlap) holds true for morphology in borderline/gray-zone tumors where the subjective attribution of 
defining criteria may cause diagnostic misinterpretation (TC vs. AC; AC vs. LCNEC; LCNEC vs. SCC) 
(Travis et al., 2015b). This results in low diagnostic reproducibility of lung NET on surgical specimens 
considered as a whole (Travis et al., 1998a; Marchevsky et al., 2001; Iyoda et al., 2007; Righi et al., 
2007; den Bakker et al., 2010; Ha et al., 2012; den Bakker and Thunnissen, 2013; Warth et al., 2013; 
Swarts et al., 2014b), apart from the distinction of the two spectrum extremes (i.e., TC from SCC) 
(Travis et al., 1998a). In biopsy samples, the challenging appreciation of solely morphologic details may 
even lead to the opposite conclusion, especially in the presence of crush artifacts (Pelosi et al., 2005).   
Grading lung NET according to the same taxonomy as that used on GEP NEN is not likely to 
be successful because of the adopted cut-off thresholds and selection biases rather than the 
incoherence per se of Ki-67 LI and mitoses to construct a histology-independent grading system (Zahel 
et al., 2012). Interestingly, when looking at survival curves of lung NET, it appears that TC are 
behaviorally quite homogeneous tumors with flat curves approaching 100% life expectation at long-term 
follow-up, whereas SCC shows steep survival curves in the first two years with a negligible fraction of 
long-term survivors at the five-year follow-up (even if this fraction is higher on surgical series) (Filosso et 
al., 2002; den Bakker et al., 2010; Travis, 2010; den Bakker and Thunnissen, 2013; Lou et al., 2013; 
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Travis, 2014; Caplin et al., 2015; Filosso et al., 2015b; Kunz, 2015; Travis et al., 2015b; Yokouchi et al., 
2015; Schmitt et al., 2016). This means that current diagnostic criteria are sufficient to extract the two 
behavioral ends, i.e. TC and SCC, from the box of lung NET. Major difficulties instead arise on AC and 
LCNEC where a non-negligible fraction of five-year survivors (up to 15–25% of patients according to 
different institutions) may be found, indicating that diagnostic criteria based solely on morphology do not 
reliably predict prognosis in these tumors (Travis et al., 1998b; Jones et al., 2004; Asamura et al., 2006; 
Righi et al., 2007; Righi et al., 2010a; Righi et al., 2010b; Rindi et al., 2014b; Filosso et al., 2015a). A 
major interpretation issue could be that the current criteria for AC or LCNEC (Table 1) are too wide 
and/or unsuitable or not sufficiently exhaustive to identify a unique category of tumors (Swarts et al., 
2013b; Toffalorio et al., 2014; Derks et al., 2016b). As a matter of fact, AC with six to ten mitoses are 
reported to have a significantly worse prognosis (Beasley et al., 2000), while the minimum of 11 mitoses 
per 2 mm2 with no theoretic upper limit required for LCNEC is unlikely to identify a homogeneous tumor 
category with regard to clinical behavior, molecular alterations or response to therapy (Veronesi et al., 
2006; Varlotto et al., 2011; Naidoo et al., 2016; Rekhtman et al., 2016). In fact, recent studies have 
confirmed that LCNEC are genetically and phenotypically heterogeneous in terms of clonal expansion 
and cell differentiation, with some of them looking like conventional NSCLC rather than SCC (Swarts et 
al., 2012; Seidel D, 2013; Pelosi et al., 2015b; Rekhtman et al., 2016). To complicate this scenario, 
there are lung NET (as well as thymus or GEP NEN) that look like AC or G2 tumors, exceeding the 
allowed mitotic count, which tautologically would be classified as LCNEC in the lung and thymus and NE 
carcinoma (NEC) in the GEP tract according to current criteria (Sobin et al., 2010; Travis et al., 2015b). 
Genetically, these tumors are more akin to AC (Rekhtman et al., 2016) or different from GEP NEC 
(Tang et al., 2016), which are thought to derive from preexisting lower grade NE tumors (Moran and 
Suster, 2000; Pelosi et al., 2015a; Tang et al., 2016).  
In this scenario, a not negligible bias is due to the low reproducibility of lung NET diagnoses 
with disturbing inter-observer variability (Travis et al., 1998a; Marchevsky et al., 2001; den Bakker et al., 
2010; Ha et al., 2012; den Bakker and Thunnissen, 2013; Swarts et al., 2014b; Marchevsky and Wick, 
2015), which allows tumors to move from one category to another. This impedes an effective cross-
study evaluation and introduces inconsistency into the survival/grading analysis. It is surprising that 
functional parameters, such as Ki-67 LI and the quantification of necrosis, have not been challenged for 
grading or even classification, crediting only mitotic count, cell features and the qualitative description of 
necrosis (Marx et al., 2015; Travis et al., 2015b). 
 
Key points: The grading of lung NET is inherently included in the current classification, which 
is in turn exclusively based on morphological criteria. Evidence is emerging, however, that morphology 
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may be inadequate to reliably predict prognosis in challenging tumors at the boundaries of intermediate 
categories, such as AC and LCNEC, with a few of these tumors behaving differently from expected.       
 
 
b) Clinicians’ requests for grading 
The therapy for lung NET depends on several factors, including histological diagnosis, 
radiology and nuclear medicine imaging, the occurrence of clinical symptoms (functioning vs. non-
functioning), tumor burden, and clinical risks, especially in quickly progressing disease and tumor traits 
for personalized therapy (Gridelli et al., 2013; Caplin et al., 2015; Pusceddu et al., 2016). The current 
WHO classification (Travis et al., 2015a), however, with its quadripartite division into four histologic 
variants, is not completely consistent with the subsequent clinical management of lung NET patients. 
This holds particularly true for metastatic disease, where therapeutically challenging tumors, such as AC 
or LCNEC, are difficult to recognize, as diagnostic criteria have been based on surgical specimens 
(Travis et al., 2015a). Notably, the diagnosis of carcinoid with no further specification would only be 
permitted on small biopsy or cytology samples. Only a suspicion of LCNEC could be raised for biopsy 
specimens (cytology is deemed unsuitable) (Travis et al., 2011; Travis et al., 2013; Caplin et al., 2015; 
Travis et al., 2015a). 
In the setting of metastatic disease, once poorly differentiated NE carcinoma has been 
reasonable excluded (Volante et al., 2011; Volante et al., 2015), it is unimportant whether TC or AC is 
encountered, because the treatment of either tumor type is mainly based on biological drugs 
(somatostatin analogues or m-TOR pathway inhibitors) and/or peptide receptor radionuclide therapy 
(PRRT) (Fazio et al., 2013; Chan and Kulke, 2014; Righi et al., 2014; Ferolla, 2015; Pelosi et al., 2015c; 
Yao et al., 2016), once the clinical balance on patients has been guided by means of imaging, 
symptoms, tumor burden, individual risks of evolving disease and the presence of actionable targets 
(Caplin et al., 2015; Pusceddu et al., 2016).  
The treatment of clinically more aggressive metastatic NET, once SCC has been ruled out (this 
corresponding to life-threatening carcinoid or LCNEC), is again independent of histology and would 
include biological therapies, PRRT or alkylating-based chemotherapy, to avoid the administration of 
platinum/etoposide (Fazio et al., 2013; Yao et al., 2016). In other words, it is clinically relevant to 
separate highly aggressive NET, the behavior and therapy of which would merge with that of classical 
SCC, from lesions showing a wider and often inexplicable range of patient prognosis, biological potential 
and clinical response. The category of these NET with intermediate prognoses could be further 
dissected according to a managerial concept of grading independent of but integrated with more 
traditional histology. In this scenario, three main practical situations could be identified: a) a completely 
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indolent-behaving tumor, which biologically corresponds to TC and, as such, could be treated with no 
particular clinical pressure; b) a low-to-moderate malignancy tumor corresponding to lower-aggressive 
AC or even some LCNEC, which are still manageable with reasonable timing according to biological 
treatments only; and c) a moderate to higher malignancy tumor corresponding to aggressive AC or 
LCNEC (the latter yet not so aggressive as true SCC, which could feature the recently described 
molecular entity of SCC-like LCNEC (Rekhtman et al., 2016)), which are managed better by biological 
treatments along with non-platinum-based chemotherapy. 
This interpretation of heterogeneously behaving and variably responsive lung NET has clinical 
and molecular correlations (Ding et al., 2008; Swarts et al., 2012; Swarts et al., 2013a; Naidoo et al., 
2016; Rekhtman et al., 2016). In the lung, this setting is similar to what has recently been suggested for 
the G3 category of GEP NEN, where the further separation into G3 NET (therapeutically and 
molecularly more akin to G2 NET) or G3 NEC (to treat with aggressive platinum-based chemotherapy) 
has been proposed on the basis of Ki-67 LI, mitotic count and tumor morphology (Bastrurk et al., 2013; 
Sorbye et al., 2013; Velayoudom-Cephise et al., 2013; Basturk et al., 2014; Rindi et al., 2014a; Basturk 
et al., 2015a; Hijioka et al., 2015; Tang et al., 2016). 
Once again, an integrated classification of lung NET that merges morphology (Travis et al., 
2015b) with an effective grading system based on or including Ki-67 LI (Rindi et al., 2014b) would be a 
desirable and clinically warranted goal. 
  
 Key points: The wide range of behaviorally intermediate tumors and some troubles in the 
multimodality therapy for AC and LCNEC, especially when dealing with metastatic lesions, with tumors 
merging with indolent TC and tumors bordering highly aggressive lesions not different from SCC, favors 
a lung-specific grading system that would help clinicians to better correlate tumor behavior with the 
choice of therapy options. 
 
 
c) Functional parameters for grading 
Even if grading derives from a pathological evaluation under microscope and should not be 
equated to prognostic scores, which however may play a role, functional imaging and molecular 
alterations of lung NET are worthwhile approaches to unravel malignancy potential by distinguishing 
indolent from aggressive tumors. 
Imaging. While computed tomography (CT) identifies lung NET as a function of extent and 
hence is useful in tumor staging, positron emission tomography techniques (PET) parallel the level of 
metabolic recruitment of tumors by measuring either fluoro-deoxy-glucose (FDG) uptake (FDG-PET) or 
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the number of somatostatin receptors by means of somatostatin receptor scintigraphy (OctreoscanTM 
and, more recently, 68Gallium PET). In recent years, these metabolic or functional images have been 
fused with morphological CT images for the improved localization of lesions (PET/CT). The likelihood of 
FDG uptake or 68Gallium binding is a function of biological properties of tumors in terms of the 
proliferative activity and/or content/bio-disponibility of somatostatin receptors (especially SSTR-2 and 
SSTR-5), which are closely associated, depending on cell differentiation and, hence, tumor grading. 
Accordingly, OctreoscanTM and 68Ga PET/CT underpin particularly low-grade lung NET, whereas the 
opposite holds true for 18F-FDG-PET/CT, which reveals high-grade tumors with different levels of 
diagnostic and prognostic accuracy based on specific biological properties. In this setting, TC revealed 
higher uptake values on 68Ga-DOTATATE-PET/CT (Kayani et al., 2009) or 68Ga-DOTA-peptide 
PET/CT, whereas 18F-FDG PET/CT was superior in discovering AC with a higher detection rate 
(Kayani et al., 2009; Venkitaraman et al., 2014; Lococo et al., 2015). Likewise, TC showed a higher 
maximal standard uptake value (SUVmax) on 68Ga-DOTATOC-PET/CT when compared to AC (Jindal 
et al., 2011; Venkitaraman et al., 2014); 18F-FDG uptake correlated significantly with Glut1, HIF-1α, 
VEGF and CD34 expression and tended to increase from low-grade to high-grade lung NET (Kaira et al., 
2013), showing high specificity for the metastatic involvement of mediastinal lymph nodes in AC (94%) 
only (Pattenden et al., 2015). The combined use of these two different PET tracers (68Ga-DOTATOC 
and 18F-FDG) may help distinguish between TC and AC, thereby providing the best NET detection rate 
(Lococo and Treglia, 2014). 
Among imaging techniques, lung magnetic resonance imaging (MRI) is gradually gaining 
relevance to clinical practice. The major limitation of lung MRI is due to technical troubles, such as low 
proton density, inhomogeneity of the magnetic field, and cardiac and respiratory motion artifacts 
(Koyama et al., 2013; Wang et al., 2014). It is, however, clinically useful in children with chronic lung 
diseases, such as cystic fibrosis, where repeated CT scans are dangerous due to the associated 
radiation burden (Ciet et al., 2016). MRI is also gaining wider acceptance for clinical grading (indolent 
versus aggressive tumors) through the use of diffusion-weighted imaging (DWI), inasmuch as it 
highlights different tumor types and intra-tumor heterogeneity that may correlate with biological behavior 
and hence tumor grading (Herneth et al., 2003). DWI is a non-invasive technique that is capable of 
probing the structure of biological tissues, thus aiding with tissue characterization. DWI exploits the 
random motion of water molecules (Brownian motion) in tissues, and the range of motion (diffusibility) of 
water molecules can be quantified by the apparent diffusion coefficient (ADC), where low ADC values 
indicate restricted diffusion. This molecular motion strictly depends on tissue structure, particularly on 
the presence of obstacles to water diffusibility such as membranes, tight junctions, fibers, 
macromolecules and cell organelles. High tumor cellular density, as can be observed in neoplasms, is 
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therefore linked to reduced water diffusibility, which can be detected and quantified using DWI on MRI. 
Liu et al. (Liu et al., 2015) demonstrated that ADC values for lung cancer were helpful in evaluating 
pathological grade and tumor cellular density, with a negative correlation between ADC values and 
tumor grade. Koyama et al. (Koyama et al., 2014) showed that DWI is more useful for the differentiation 
of SCLC from NSCLC than MR-STIR (short-tau inversion recovery sequence, a solely morphological 
sequence), with SCLC exhibiting significantly lower ADC values than NSCLC. Despite these studies, the 
correlation between ADC values and tumor cellularity is not always clear, and it can be influenced by 
varying technical or environmental factors (degree of necrosis and/or microstructural changes preceding 
necrosis) (Matoba et al., 2007; Uto et al., 2009). 
To the best of our knowledge, there are no studies attempting to characterize different 
subgroups of lung NET in order to establish a relationship between imaging and histological grading. 
However, an inverse correlation between ADC values and Ki-67 LI or tumor cellularity is on record for 
pancreatic NET (Wang et al., 2011), supporting a theoretic application to lung NET. In the near future, a 
better mathematical fitting of a non-Gaussian diffusion model to the DWI signal decay, as compared to 
mono-exponential analysis, could be expected for lung NET. Recently, Heusch et al. (Heusch et al., 
2013) studied an NSCLC population comprised of two LCNEC, demonstrating that the simultaneous 
PET and non-Gaussian diffusion acquisition were feasible in these tumors with well-correlated SUV 
values. 
Novel molecular imaging approaches to lung NET have been developed in recent years, taking 
advantage of hormones and products secreted by tumor cells, such as 18F-3,4-dihydrophenylalanine 
(DOPA), which can be used to trace amine precursor uptake in lung carcinoids (Jager et al., 2008). 
These newer agents, however, are more useful to stage the disease rather than to grade NET (Hicks, 
2010). 
  
 Key points: Although there have been few systematic studies on the relationship between 
imaging and histologic grading in lung NET to date, PET scan and diffusion-weighted imaging upon MRI 
are emerging as promising techniques to unravel the level of biological recruitment of these tumors. 
 
 Molecular studies. A comprehensive study of the molecular landscape underlying the 
pathophysiology of lung NETs is required to improve grading and support therapy decisions. Genomics 
and systems biology approaches can shed light on the fundamental mechanisms that lead to pathology 
development, exploiting information at the cellular level to tackle the inherent heterogeneity of cancer 
disease, enhancing the concept of diagnosis and, consequently, of treatment, toward so-called precise 
medicine. 
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 A systematic analysis of genomic alterations in very large data sets of lung cancer samples has 
allowed investigators to characterize sequence variants of the main histological subgroups, including 
NETs. While carcinoids did not present significant somatic copy number alterations, SCLC showed 
significantly amplified chromosomal regions at 1p (MYCL1), 2p (MYCN), 5p, 8p (FGFR1) and 19q 
(CCNE1) and deletions of 3p (FHIT) and 13q (RB1) (Seidel D, 2013). LCNECs represent a very 
heterogeneous group, showing genomic alterations and expression profiling pertinent to other histologic 
subtypes, which have been deeply characterized in a recent study (Rekhtman et al., 2016). This 
analysis identified distinct LCNEC subtypes: SCLC-like, characterized by TP53 and RB1 co-
mutation/loss and other SCLC-type alterations along with higher proliferative activity of SCLC-like 
tumors; NSCLC-like, characterized by the lack of co-altered TP53 and RB1 and the occurrence of 
NSCLC-typical mutations (STK11, KRAS, KEAP1) along with exclusive exocrine differentiation marker 
expression in NSCLC-like tumors; and carcinoid-like, characterized by less frequent genetic alterations 
and the presence of mutations in the MEN1 gene (Rekhtman et al., 2016). 
 The occurrence of the MEN1 mutation along with decreased expression was associated with 
poor prognosis in a specific study on carcinoids (Swarts et al., 2014a). The same holds true for low 
expression levels of CD44 and OTP genes (Swarts et al., 2013b; Swarts et al., 2013a). Furthermore, the 
two genes CEACAM1 and GC were identified as potential IHC markers that can be used to distinguish 
between typical and atypical carcinoids, because they are significantly upregulated in the latter subtype 
(Toffalorio et al., 2014). 
 More generally, a signature of 26 testis-specific and placental-specific genes has been 
identified, with ectopic expression in adult somatic tissues associated with the aggressiveness of tumors 
and characterized in lung cancer (Rousseaux et al., 2013). Indeed, it is a recurrent finding that 
transcriptional programs regulating developmental processes can be triggered unexpectedly, leading to 
cancer development and progression. Specifically, it was observed in a study involving 293 lung cancer 
patients, including lung NET, that tumors expressing at least 3 of these 26 genes had an aggressive 
phenotype, leading to quick relapse and/or metastasis and very low survival. Interestingly, the 
prognostic power of this 26-gene set was not dependent on clinical stage or histological subtype, and it 
proved to be very efficient for overall survival prediction among early-stage patients (Rousseaux et al., 
2013), as well as for tumor grading. This aberrant activation of normally silent developmental genes was 
mainly associated with epigenetic deregulation, such as the demethylation of silenced promoters or 
other chromatin alterations. 
 Several epigenetic modifications have been correlated directly with grade in lung NET 
(Karpathakis et al., 2013). For example, RASSF1 promoter methylation status may be used as a 
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biomarker for grading (Pelosi et al., 2010), and the presence of the two histone markers H4KA16 and 
H4KM20 inversely correlates with grade and Ki67 LI (Li et al., 2011). 
 There are different opportunities for the regulation of gene expression. MicroRNA, a class of 
noncoding RNAs, exert this action at the post-transcriptional level. In a recent study (Mairinger et al., 
2014), 12 microRNAs have been found to be differentially expressed across lung NET, eight showing a 
negative and four a positive correlation with grade. However, this analysis has been accomplished on 
12 pulmonary NET patients, so, although it is very tempting to draw conclusions about lung NET biology 
along with the identification of effective biomarkers, further validation on a wider sample size is needed 
to confirm the reproducibility and feasibility of these results. 
  
 Key points: Several investigations about the molecular profiling of pulmonary NET have been 
reported so far, though this disease category has been less studied. A comprehensive molecular portrait 
of lung NET, integrating different levels of evidence, could also improve grading procedures and lead to 
new and more specific therapeutic options derived from a reliable estimation of the cellular disease 
potential based on the characterization of its gene expression program. 
 
 
d) Ki-67 labeling index for grading 
The role of KI-67 LI in the grading of lung NET, expressed as the percentage of decorated 
tumor cells showing nuclear compartmentalization (usually counting 2000 tumor cells in areas of highest 
staining or hot spots) is still a debated matter (Pelosi et al., 2014c) at variance with its well-established 
use in GEP NEN (Pelosi et al., 1996; Rindi et al., 2006; Klimstra et al., 2010b; Klimstra et al., 2010a; 
Sobin et al., 2010; Rindi et al., 2012; Rindi et al., 2014a; Klimstra et al., 2015; Klimstra, 2016). Critics 
have argued about inter-observer reproducibility (Travis et al., 1998a; Marchevsky et al., 2001; den 
Bakker et al., 2010; Ha et al., 2012; den Bakker and Thunnissen, 2013; Swarts et al., 2014b; 
Marchevsky and Wick, 2015), controversies related to manual or automated assessment (Walts et al., 
2012; Warth et al., 2013), the overlap of adjacent tumor categories (TC vs. AC; AC vs. LCNEC; LCNEC 
vs. SCC) because of imperfect co-linearity with accepted diagnostic criteria (mitotic count and necrosis) 
(Pelosi et al., 2014a; Pelosi et al., 2014b; Pelosi et al., 2015c), the unsuitability of cytology or biopsy 
samples for reliable quantification due to the wide spectrum of tumor differentiation or intra-tumor 
heterogeneity (Pelosi et al., 2014c; Pelosi et al., 2015c; Travis et al., 2015b) and the role of independent 
prognosticators (Greenberg et al., 1987; Costes et al., 1995; Granberg et al., 2000; Van Eeden et al., 
2002; Pelosi et al., 2003a; Pelosi et al., 2003b; Igarashi et al., 2004; Das-Neves-Pereira et al., 2008; 
Rugge et al., 2008; Skov et al., 2010; Grimaldi et al., 2011; Walts et al., 2012; Zahel et al., 2012) (and 
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hence tumor-grading forerunners) in multivariate analysis (Zahel et al., 2012; Rindi, Klersy, et al., 2014). 
Incidentally, any reference to a grading system dealing with KI-67 LI in lung NET was not mentioned in 
the 2015 WHO classification, where the primacy of histology was again reaffirmed (Travis et al., 2015b).  
Recent reproducibility studies in lung NET, however, have revealed less than 1.5% of 
variability for Ki-67 LI, with an out-performance over mitotic count with regard to inter-observer 
agreement (Walts et al., 2012; Warth et al., 2013). Many of the issues raised, however, are not different 
from those that accompanied the birth and development of an effective grading system in GEP NEN 
based on KI-67 LI and mitotic count (Rindi et al., 2006; Klimstra et al., 2010b; Klimstra et al., 2010a; 
Sobin et al., 2010; Rindi et al., 2012; Rindi et al., 2014a; Klimstra et al., 2015; Klimstra, 2016), thus 
indicating that there could still be room for an integrated use of Ki-67 LI through a revised policy of 
tumor grading attribution in lung NET. Although Ki-67 LI has been ranked among diverse histologic 
variants in the 2015 WHO classification (TC: ≤5%; AC: up to 20%; LCNEC: 40–80%; SCC: 50–100%), 
the only current recommended use of this marker concerns the diagnostic separation of TC or AC on 
one hand and SCC on the other, especially in small biopsy or cytology samples, which is by far superior 
to necrosis, mitotic count and NE markers (Helpap and Kollermann, 2001; Lin et al., 2003; Aslan et al., 
2005; Pelosi et al., 2005; Zheng et al., 2013; Travis et al., 2015b). 
Many studies have addressed the prognostic role of Ki-67 LI in lung NET, especially TC and 
AC, sometimes with conflicting results in multivariate analysis (Greenberg et al., 1987; Costes et al., 
1995; Granberg et al., 2000; Van Eeden et al., 2002; Pelosi et al., 2003a; Pelosi et al., 2003b; Igarashi 
et al., 2004; Das-Neves-Pereira et al., 2008; Rugge et al., 2008; Skov et al., 2010; Grimaldi et al., 2011; 
Walts et al., 2012; Zahel et al., 2012), whereas few have investigated the relevance of Ki-67 LI, alone or 
jointly with others, to construct a grading system (Zahel et al., 2012; Rindi et al., 2014b). Other works 
have correlated the distribution of Ki-67 LI with tumor grade according to the usual diagnostic 
categorization, thus reflecting well-known variations in tumor differentiation rather than introducing a true 
grading system based on this marker (Tsuta et al., 2011; Zheng et al., 2013). There is co-linearity but 
not a perfect relationship among Ki-67 LI, mitosis and necrosis. This co-linearity may become a 
resource to develop a synergistic grading system only if specific and independent cut-off thresholds are 
devised for each parameter in these tumors (Rindi et al., 2014b). 
At variance with GEP NEN (Yang et al., 2011), comparative studies on the prevalence of Ki-67 
LI, necrosis and mitosis in paired biopsies and surgical specimens of lung NET are still lacking. It is, 
however, clinically important to characterize tumor aggressiveness, especially in the context of 
metastatic disease, when considering the inconsistency of the current classification on biopsy samples 
(Pelosi et al., 2005; Travis et al., 2015b). We recently found that Ki-67 LI was accurate for biopsy 
samples as surgical specimens by stratifying tumors for histological subtypes, once hot-spot areas were 
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identified in either type of material, whether 2000 cells, 2 mm2-spanning tumor regions or the entire 
biopsy fragments were counted (Pelosi et al, manuscript in preparation). This investigation could be 
prodromal to the development of an effective grading system for lung NET biopsies based mainly on Ki-
67 LI, inasmuch as it is superior to evaluations of mitosis and necrosis in this type of material (Pelosi et 
al., 2005). 
 
Key points: There is no consensus on the use of Ki-67 LI as a diagnostic tool, prognosticator 
or grading maker in lung NET due to either histology-dependent-criteria for classification or 
methodological-biological reasons. However, Ki-67 LI is by far superior to any other indicator of tumor 
aggressiveness in lung NET biopsies, such as necrosis and mitotic count. As most lung NET are 
metastatic at the time of the initial diagnosis, there is clinical urgency to maximize Ki-67 LI assessment 
for this type of material. 
 
 
e) Towards a proposal of integrated pathology grading 
 The 2015 WHO terminology for lung NET are known worldwide, with extensive clinical 
experience related to diagnosis, molecular alterations, prognosis and therapy planning. In particular, TC, 
AC, LCNEC and SCLC are perceived as distinctive tumor entities so it would appear reductive to 
categorize TC as G1, AC as G2 and LCNEC and SCC as G3 tumors. Nonetheless, inconsistencies in 
diagnosis, therapy, and the prognostic/predictive value of classification at the level of individual tumors 
lead to the need for a global re-thinking of lung NET (Pelosi et al., 2014a; Pelosi et al., 2015c). 
Furthermore, tumor grading in NET is so familiar to most clinicians that it should not be so hard or 
untimely to extend this concept to lung NET. 
 As there is always some potential inter-observer variation due to either subjective interpretation 
or heterogeneous intra-tumor distribution of defining criteria, a multi-parametric evaluation with different 
cut-off levels for each parameter could minimize these drawbacks (Hochwald et al., 2002; McCall et al., 
2013; Rindi et al., 2014b). In this frame of mind, we have recently proposed an innovative grading 
system based on the study of 348 surgically resected lung NET belonging to all histologic variants (105 
TC, 75 AC, 86 LCNEC and 82 SCC), which were investigated for Ki-67 LI, mitotic count and necrosis 
quantification (Rindi et al., 2014b). These parameters had been chosen because they reflected 
functionally generalized but differentially regulated mechanisms of growth and maintenance in tumor 
development (Pelosi et al., 2014b). The advantage of this approach would be that tumor aggressiveness 
could be deciphered from three different but converging angles, based on the premise that using more 
parameters would lead to a greater likelihood of compensating for inconsistencies among them. 
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Interestingly, two of these three parameters are both defining criteria in the 2015 WHO classification on 
lung NET (Travis et al., 2015b) and valuable effectors of grading on GEP NEN (Rindi et al., 2006; Sobin 
et al., 2010; Rindi et al., 2012; Rindi et al., 2014a). Each parameter was tiered according to three 
expression levels, which were independent of each other at multivariate analysis (Table 2). Accordingly, 
G1 tumors were defined if at least two out of three parameters were at Level 1; G2 if at least two out of 
three parameters were at Level 2; and G3 if at least two out of three parameters were at Level 3. The 
resulting grading system outperformed each individual parameter in predicting overall patient survival, 
resulting in a G1 to G3 grading system showing minimal overlap of 95% confidence intervals among 
defining categories. Interestingly, all TC clustered into the G1 category, whilst a fraction of LCNEC and 
even SCC entered the G2 category in keeping with the clinical observation that a few of these patients 
pursue an unexpectedly less aggressive clinical course (Brock et al., 2005; Tsuchiya et al., 2005; 
Asamura et al., 2006; Asamura et al., 2008; Abedallaa et al., 2012). As far as the challenging category 
of AC was concerned, it was split into all tumor grades to reflect the inherent behavioral heterogeneity of 
these tumors, some of which behave quite similarly to TC, whereas others fit with high-grade NET (Rindi 
et al., 2014a). As this grading system was set up on surgical specimens, a further evolution could be 
identifying adequate criteria for small biopsies, which may prove to be particularly effective in metastatic 
lung NET as happens on GEP-NET (Rindi et al., 2006; Klimstra et al., 2010b; Klimstra et al., 2010a; 
Sobin et al., 2010; Rindi et al., 2012; Klimstra et al., 2015; Klimstra, 2016). 
This proposal could be stepwise integrated with the 2015 WHO classification according to the 
following procedure: Step 1, classify tumors according to WHO; Step 2, grade tumors separately by 
itemizing them into G1 to G3 categories; Step 3, integrate the grade assignment with traditional 
histology. Accordingly, it is possible to formulate a new terminology, namely Lu-NET G1, Lu-NET G2 
and Lu-NET G3, which would be managerially oriented to handle lung NET tumors with similar histology 
that behave differently. Briefly, Lu-NET G1 would indicate low-grade malignant TC or AC; Lu-NET G2, 
intermediate-grade malignant AC with a contribution of LCNEC or even SCC; Lu-NET G3, high-grade 
malignant SCLC and LCNEC and occasional AC patients (Table 3). This practical approach could avoid 
over-treating with platinum-etoposide AC and LCNEC/SCC patients destined to be better classified as 
Lu-NET G1 and Lu-NET G2, respectively, as well as under-treating AC patients categorized as 
belonging to Lu-NET G3 with somatostatin analogues. At variance with GEP NEN, cell differentiation 
would no longer be considered in lung NET because the same histologic variant could be diversely 
distributed across different risk categories for death or treatment. A further evolution of this grading 
system could be used to interpret the intra-tumor heterogeneity of Ki-67 LI in terms of asymmetry, 
kurtosis and cell entropy to unravel the behavioral properties of these tumors (Pelosi et al, manuscript in 
preparation). 
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Key points: A grading system based on Ki-67 LI, necrosis and mitotic count evaluation in 
surgical specimens of lung NET is clinically useful to tune the most appropriate therapy in individual 
tumor categories, especially for biopsy samples and metastatic disease where Ki-67 LI is by far superior 
to necrosis and mitotic count. 
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Conclusion 
 The basic question is not whether to grade or not to grade lung NET but rather how to grade 
these tumors for operational decisions in the management of individual cancer patients. Lung NET 
shows profound differences in terms of epidemiological, molecular, clinical, pathological and behavioral 
traits, which however converge into a three-tier prognostic spectrum encompassing tumors of low, 
intermediate and high malignancy. As conventional histology is not completely apt to reliably predict 
prognosis or decipher therapy options, especially in metastatic disease, a concept of grading is clinically 
justified for personalizing treatments. This tumor grading should be based on diverse parameters to 
account for either intra-tumor heterogeneity or subjective interpretation when assessing defining criteria. 
The goal is to integrate well-known histology with an innovative grading system to better re-classify lung 
NET for clinical purposes. Whether Ki-67 LI could play a role in grading biopsy samples should be a 
matter of further investigation. 
 
 
Future perspective 
 Morphologic classification is destined to remain a backbone in the diagnosis, prognosis and 
clinical management of lung NET in virtue of its relationship with tumor behavior and clinical implications. 
It is, however, clinically warranted to implement this traditional approach with a biologically more 
adapted grading system based on proliferation parameters, such as Ki-67 LI, especially in the setting of 
metastatic disease where morphology may be more deceptive. Recent improvements in the therapy of 
lung NET will increase even more the clinical relevance of such grading systems in the management of 
these tumor patients.     
 
 
Bullet points 
♦ The current WHO classification is still the backbone for diagnosis, prognosis and clinical 
management of lung NET 
♦ TC are low malignant, AC intermediate malignant and SCLC/LCNEC high malignant tumors, 
with some homologies with G1 and G2 NET and G3-NEC of the GEP tract, respectively 
♦ Tumor grading is tautologically included in the current classification, but there is a growing 
awareness on the clinical utility of an integrated grading system to personalize treatments especially in 
the handling of metastatic lung NET 
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♦ Stepwise combination of grading and histology (Step 1: to classify tumors according to 
WHO; Step 2: to grade tumors separately by itemizing them into G1 to G3 categories; Step 3: to 
integrate the grade assignment with traditional histology according to Lu-NET G1, Lu-NET G2 and Lu-
NET G3 terminology) could translate lung NET with similar histology into a more robust correlation with 
clinical behavior and treatment. 
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Figure legends 
Figure 1 A-D. A case of peripherally located small cell carcinoma featuring well retained 
neuroendocrine differentiation levels in the form of rosettes and trabecular architecture, along with 
nuclear molding (inset) and extensive necrosis (white asterisk) consistent with high-grade 
neuroendocrine tumors (A). This tumor exhibited strong chromogranin A decoration witnessing high 
content of neuroendocrine secretion granules (B), along with diffuse and intense synaptophysin 
accumulation (C), focal cytokeratin pool AE1-AE3 reactivity (C, inset) and very high Ki-67 labeling index 
(D), revealing common properties of high-grade tumors with well retained neuroendocrine differentiation. 
 
 
Table legends 
Table 1. Diagnostic features for lung neuroendocrine tumors according to the 2015 WHO 
classification. 
Table 2. Grading system in lung neuroendocrine tumors based on a tripartite evaluation of 
parameters. 
Table 3. Integrated classification on lung neuroendocrine tumors. 
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Table 1. Diagnostic features for lung neuroendocrine tumors according to the 2015 WHO classification 
 
 Variable Typical carcinoid Atypical carcinoid 
Large-cell 
neuroendocrine 
carcinoma 
Small-cell carcinoma 
Neuroendocrine 
morphology yes (organoid) yes (organoid) yes (organoid) yes (nuclear features) 
Cytological criteria no no yes yes 
Mitoses/2 mm2 1 2-10 ≥ 11 ≥ 11 
Necrosis no punctate extensive extensive 
Use of 
immunohistochemistry recommended recommended defining recommended 
Combined variant no no yes yes 
Chromogranin A and 
synaptophysin positive positive positive 80-90% positive 80-90% 
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Ki-67 labeling index up to 5% up to 25% 40-80% 50-100% 
 
 
 
 
 
 
 
 
 
Table 2. Grading system in lung neuroendocrine tumors based on a tripartite evaluation of parameters 
Cut-off levels 
Variables 
Mitoses                                           
(10 HPF or 2 mm2) Ki-67 labeling index (%) Necrosis quantitation 
Level 1 2 < 4 absent 
Level 2 >2 - 47 4 - 25 ≤ 10% 
Level 3 > 47 ≥ 25 > 10% 
 
Ki-67 labeling index indicates the percentage of immunoreactive tumor cells. For details on application of the grading see the 
text  
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Table 3. Integrated classification on lung neuroendocrine tumors 
 
            
Category Histology Decision levels 
Variables 
Mitoses                         
(10 HPF or 2 mm2) 
Ki-67 labeling index 
(%) 
Necrosis 
quantitation 
Lu-NET G1 TC, AC 2 at level 1 2 < 4 absent 
Lu-NET G2 AC, LCNEC, SCC 2 at level 2 >2 to 47 4 - 25 ≤ 10% 
Lu-NET G3 LCNEC, SCC, AC 2 at level 3 > 47 ≥ 25 > 10% 
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